Related Experiment Video
Updated: May 3, 2026

Biotinylated Cell-penetrating Peptides to Study Intracellular Protein-protein Interactions
Published on: December 20, 2017
A cell-penetrating peptide based on the interaction between c-Src and connexin43 reverses glioma stem cell phenotype
E Gangoso1, C Thirant2, H Chneiweiss2
1Departamento de Bioquímica y Biología Molecular, Instituto de Neurociencias de Castilla y León (INCYL), Universidad de Salamanca, Salamanca, Spain.
Abstract:
Connexin43 (Cx43), the main gap junction channel-forming protein in astrocytes, is downregulated in malignant gliomas. These tumors are composed of a heterogeneous population of cells that include many with stem-cell-like properties, called glioma stem cells (GSCs), which are highly tumorigenic and lack Cx43 expression. Interestingly, restoring Cx43 reverses GSC phenotype and consequently reduces their tumorigenicity. In this study, we investigated the mechanism by which Cx43 exerts its antitumorigenic effects on GSCs. We have focused on the tyrosine kinase c-Src, which interacts with the intracellular carboxy tail of Cx43. We found that Cx43 regulates c-Src activity and proliferation in human GSCs expanded in adherent culture. Thus, restoring Cx43 in GSCs inhibited c-Src activity, which in turn promoted the downregulation of the inhibitor of differentiation Id1. Id1 sustains stem cell phenotype as it controls the expression of Sox2, responsible for stem cell self-renewal, and promotes cadherin switching, which has been associated to epithelial-mesenchymal transition. Our results show that both the ectopic expression of Cx43 and the inhibition of c-Src reduced Id1, Sox2 expression and promoted the switch from N- to E-cadherin, suggesting that Cx43, by inhibiting c-Src, downregulates Id1 with the subsequent changes in stem cell phenotype. On the basis of this mechanism, we found that a cell-penetrating peptide, containing the region of Cx43 that interacts with c-Src, mimics the effect of Cx43 on GSC phenotype, confirming the relevance of the interaction between Cx43 and c-Src in the regulation of the malignant phenotype and pinpointing this interaction as a promising therapeutic target.
Insights
Restoring connexin 43 (Cx43) in glioma stem cells (GSCs) inhibits c-Src activity, downregulating Id1 and Sox2. This reverses GSC stemness and reduces tumor growth, offering a potential therapeutic strategy.
Area of Science:
- Neuroscience
- Cancer Biology
- Cell Biology
Background:
- Malignant gliomas contain glioma stem cells (GSCs) that lack connexin 43 (Cx43) and exhibit high tumorigenicity.
- Restoring Cx43 expression in GSCs reverses their stem-cell-like properties and reduces tumor-forming potential.
Purpose of the Study:
- To elucidate the molecular mechanism underlying the antitumorigenic effects of Cx43 in GSCs.
- To investigate the role of the tyrosine kinase c-Src in Cx43-mediated GSC regulation.
Main Methods:
- Investigated the interaction between Cx43 and c-Src in human GSCs.
- Analyzed the impact of Cx43 restoration and c-Src inhibition on Id1, Sox2, and cadherin expression.
- Utilized a cell-penetrating peptide mimicking the Cx43-c-Src interaction region.
Main Results:
- Cx43 regulates c-Src activity and proliferation in GSCs.
- Restoring Cx43 or inhibiting c-Src led to decreased Id1 and Sox2 expression.
- These changes promoted a switch from N-cadherin to E-cadherin, indicative of reduced epithelial-mesenchymal transition.
Conclusions:
- Cx43 inhibits GSC stemness and tumorigenicity by downregulating c-Src activity, subsequently reducing Id1 and Sox2 levels.
- The Cx43-c-Src interaction is crucial for maintaining the GSC malignant phenotype.
- A peptide targeting this interaction offers a potential therapeutic strategy for gliomas.
More Related Videos
10:28Flow Cytometry-based Drug Screening System for the Identification of Small Molecules That Promote Cellular Differentiation of Glioblastoma Stem Cells
Published on: January 10, 2018
09:26Method for Novel Anti-Cancer Drug Development using Tumor Explants of Surgical Specimens
Published on: July 29, 2011